Pillar Biosciences Partners with AstraZeneca to Expand Access to NGS Liquid Biopsy Panels
Slice of Healthcare Team
09/16/2024
Key Highlights
- Partnership to expand molecular testing across European and UK markets.
- Focus on rapid, in-house cancer diagnosis using NGS liquid biopsy panels.
- Pillar's oncoRevealTM LBx panels offer high sensitivity with results in less than three days.
- Scalable sequencing for economic value using Illumina NextSeq™.
Source: PR Newswire
Notable Quotes
“ Access to cost-effective, easy-to-use, distributed NGS kits for liquid biopsy testing are critical to support local laboratories in providing clinically actionable results to oncologists and supporting critical treatment decisions for cancer patients globally. ”
Dan Harma, Chief Commercial Officer at Pillar Biosciences
“ We are committed to expanding global patient access to biomarker testing, and decentralized NGS solutions are key to this strategy. ”
John Longshore, Head of Scientific Affairs, Global Oncology Diagnostics at AstraZeneca
Heading
LetsGetChecked Appoints Francheska Werner as Head of Provider Genomics Hiring News News Read More Chris-Anne Roque ixlayer Launches ‘ixEngage’: Direct-to-Patient Solution for Biopharma News Product News Read More Chris-Anne Roque Candid Health Secures $29M Series B to Automate Healthcare Billing M&A News News Read More Chris-Anne Roque Novotech Appoints Dr. Yooni Kim as Managing Director for APAC Region Hiring News News Read More Chris-Anne Roque ŌURA Expands into Metabolic Health with Acquisition of Veri M&A News News Read More Chris-Anne Roque HAYA Therapeutics Appoints Jordan Shin, M.D., Ph.D. as Chief Medical Officer Hiring News News Read More Chris-Anne Roque
